专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08822644B2 Method of treating cancer comprising a VEGF-B antagonist 有权
标题翻译：治疗包含VEGF-B拮抗剂的癌症的方法
公开(公告)号：US08822644B2
公开(公告)日：2014-09-02
申请号：US11659179
申请日：2005-08-02
申请人： Andrew Nash , Felicity Meredith Dunlop , Manuel Baca , Louis Jerry Fabri , Pierre David Scotney
发明人： Andrew Nash , Felicity Meredith Dunlop , Manuel Baca , Louis Jerry Fabri , Pierre David Scotney
IPC分类号： C07K16/22 , C12P21/08 , C12N5/10 , C12N15/13 , C12N5/07 , A61K39/00
CPC分类号： C07K16/22 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/73 , C07K2317/76
摘要： The present invention relates generally to the field of cancer therapy and prophylaxis. More particularly, the present invention provides growth factor antagonists which inhibit the growth of cancers including tumors and pre-cancerous tissue. Even more particularly, the present invention is directed to antagonists of vascular endothelial growth factor-B and their use to inhibit the growth of cancer including tumor tissue and pre-cancerous tissue.
摘要翻译：本发明一般涉及癌症治疗和预防领域。更具体地，本发明提供了抑制癌症包括肿瘤和癌前组织的生长的生长因子拮抗剂。更具体地，本发明涉及血管内皮生长因子B的拮抗剂及其抑制癌症生长的用途，包括肿瘤组织和癌前组织。

2. 发明申请

US20080260729A1 Method of Treating Cancer Comprising a Vegf-B Antgonist 有权
标题翻译：治疗包含Vegf-B拮抗剂的癌症的方法
公开(公告)号：US20080260729A1
公开(公告)日：2008-10-23
申请号：US11659179
申请日：2005-08-02
申请人： Andrew Nash , Felicity Meredith Dunlop , Manuel Baca , Louis Jerry Fabri , Pierre David Scotney
发明人： Andrew Nash , Felicity Meredith Dunlop , Manuel Baca , Louis Jerry Fabri , Pierre David Scotney
IPC分类号： A61K39/395 , A61K31/7052 , A61P35/00 , C07K16/00 , C07H21/00 , C12N15/63 , C12N1/00 , C12N5/00 , C12P21/00
CPC分类号： C07K16/22 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/73 , C07K2317/76
摘要： The present invention relates generally to the field of cancer therapy and prophylaxis. More particularly, the present invention provides growth factor antagonists which inhibit the growth of cancers including tumors and pre-cancerous tissue. Even more particularly, the present invention is directed to antagonists of vascular endothelial growth factor-B and their use to inhibit the growth of cancer including tumor tissue and pre-cancerous tissue.
摘要翻译：本发明一般涉及癌症治疗和预防领域。更具体地，本发明提供了抑制癌症包括肿瘤和癌前组织的生长的生长因子拮抗剂。更具体地，本发明涉及血管内皮生长因子B的拮抗剂及其抑制癌症生长的用途，包括肿瘤组织和癌前组织。

3. 发明授权

US07517524B2 Immunointeractive molecules 有权
标题翻译：免疫相互作用分子
公开(公告)号：US07517524B2
公开(公告)日：2009-04-14
申请号：US11652711
申请日：2007-01-12
申请人： Andrew Nash , Giuseppe Maccarone , Pierre David Scotney
发明人： Andrew Nash , Giuseppe Maccarone , Pierre David Scotney
IPC分类号： A61K39/395 , C12P21/08 , C07K16/00 , C07K16/18 , C07K16/22
CPC分类号： C07K14/52 , C07K14/71
摘要： The present invention relates generally to immunointeractive molecules and more particularly antibodies which bind to vascular endothelial growth factor-B (VEGF-B) or its functional or structural equivalent and inhibit the biological activity of VEGF-B. In particular, the present invention relates to deimmunized such as humanized or human antibodies that bind to VEGF-B and inhibit the biological activity of VEGF-B. These antibodies have uses in the treatment or prevention of diseases associated with perturbations in normal vasculogenesis or angiogenesis or vascular remodelling. The present invention further contemplates a method of modulating diseases associated with perturbations in normal vasculogenesis or angiogenesis or vascular remodelling by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies which bind to VEGF-B and block the biological activity of VEGF-B. Accordingly, a method of screening for inhibitors of the biological activity of VEGF-B is also provided.
摘要翻译：本发明一般涉及免疫相互作用分子，更具体地涉及结合血管内皮生长因子-B（VEGF-B）或其功能或结构等同物并且抑制VEGF-B生物活性的抗体。特别地，本发明涉及与VEGF-B结合并抑制VEGF-B的生物学活性的去免疫化的人源化或人抗体。这些抗体在治疗或预防与正常血管发生或血管生成或血管重构中的扰动相关的疾病中具有用途。本发明进一步考虑了通过施用本发明的抗体调节与正常血管发生或血管发生或血管重构中的扰动相关的疾病的方法。本发明还提供了可用于鉴定结合VEGF-B并阻断VEGF-B的生物学活性的抗体的测定系统。因此，还提供了筛选VEGF-B生物活性抑制剂的方法。

4. 发明申请

US20080057517A1 Methods of regulating cytokine signalling 审中-公开
标题翻译：调节细胞因子信号传导的方法
公开(公告)号：US20080057517A1
公开(公告)日：2008-03-06
申请号：US11818589
申请日：2007-06-15
申请人： Sandra Nicholson , Manuel Baca , Nicos Nicola , Douglas Hilton , Jian Zhang , Louis Fabri , Andrew Nash
发明人： Sandra Nicholson , Manuel Baca , Nicos Nicola , Douglas Hilton , Jian Zhang , Louis Fabri , Andrew Nash
IPC分类号： G01N33/53
CPC分类号： G01N33/6863
摘要： The present invention relates generally to a method for regulating cytokine signalling and agents useful for same. The method of the present invention is predicated in part on the identification of the molecular target of suppressor of cytokine signalling (SOCS) interaction in controlling cytokine signalling. The identification of the molecular target permits the development of assays to screen for a range of agonists and antagonists useful in modulating cytokine function. The present invention further provides, therefore, screening assays and more particularly high through-put screening assays for agonists and antagonists of SOCS-receptor interaction. Such agonists and antagonists are useful in the manufacture of medicaments for controlling cytokine signalling. Control of cytokine signalling is important for the treatment of a range of conditions including cancer, inflammatory conditions, immunological disorders and any other conditions involving aberrations of signal transduction.
摘要翻译：本发明一般涉及用于调节细胞因子信号传导的方法和可用于其的试剂。本发明的方法部分地基于在控制细胞因子信号传导中识别细胞因子信号传导抑制剂（SOCS）相互作用的分子靶标。分子靶标的鉴定允许开发测定以筛选可用于调节细胞因子功能的一系列激动剂和拮抗剂。因此，本发明进一步提供用于SOCS-受体相互作用的激动剂和拮抗剂的筛选测定和更特别的高通量筛选测定。这样的激动剂和拮抗剂可用于制备用于控制细胞因子信号传导的药物。细胞因子信号传导的控制对于治疗一系列病症（包括癌症，炎性病症，免疫学障碍和涉及信号转导异常的任何其他病症）是重要的。

5. 发明申请

US20050058645A1 Monoclonal antibody against Interleukin-13 receptor alpha 1 (IL-13Ralpha1) 有权
标题翻译：白细胞介素-13受体α1单克隆抗体（IL-13Rα1）
公开(公告)号：US20050058645A1
公开(公告)日：2005-03-17
申请号：US10850270
申请日：2004-05-20
申请人： Felicity Dunlop , Manuel Baca , Andrew Nash , Louis Fabri , Douglas Hilton , Nicos Nicola
发明人： Felicity Dunlop , Manuel Baca , Andrew Nash , Louis Fabri , Douglas Hilton , Nicos Nicola
IPC分类号： C07K16/28 , C12N5/20 , A61K39/395 , C07K16/24
CPC分类号： C07K16/2866 , C07K2317/24 , C07K2317/55 , C07K2319/00
摘要： The present invention relates generally to antibodies that bind to the Interleukin-13 receptor α1 chain (IL-13Rα1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13Rα1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13Rα1/ligand interaction is also provided.
摘要翻译：本发明一般涉及结合白细胞介素-13受体α1链（IL-13Rα1）并通过IL-13和/或IL-4拮抗IL-13受体介导的信号传导的抗体。更具体地说，本发明为哺乳动物，特别是IL-13Rα1提供人源化或人抗体。这些抗体在治疗或预防IL-13和/或IL-4介导的疾病或病症中具有应用。本发明进一步考虑通过施用受试者抗体调节IL-13和/或IL-4介导的疾病或病症的方法。本发明还提供了可用于鉴定通过IL-13受体复合物调节IL-13和/或IL-4信号传导的抗体或其它试剂的测定系统。因此，还提供了筛选IL-13Rα1/配体相互作用的调节剂的方法。

6. 发明授权

US07256007B2 Methods of regulating cytokine signalling 失效
标题翻译：调节细胞因子信号传导的方法
公开(公告)号：US07256007B2
公开(公告)日：2007-08-14
申请号：US10221125
申请日：2001-03-09
申请人： Sandra Elaine Nicholson , Manuel Baca , Nicos A. Nicola , Douglas Hilton , Jian Guo Zhang , Louis Fabri , Andrew Nash
发明人： Sandra Elaine Nicholson , Manuel Baca , Nicos A. Nicola , Douglas Hilton , Jian Guo Zhang , Louis Fabri , Andrew Nash
IPC分类号： G01N33/53 , G01N33/00 , C07K1/00 , C07K14/00
CPC分类号： G01N33/6863
摘要： The present invention relates generally to a method for regulating cytokine signaling and agents useful for same. The method of the present invention is predicated in part on the identification of the molecular target of suppressor of cytokine signaling (SOCS) interaction in controlling cytokine signaling. The identification of the molecular target permits the development of assays to screen for a range of agonists and antagonists useful in modulating cytokine function. The present invention further provides, therefore, screening assays and more particularly high through-put screening assays for agonists and antagonists of SOCS-receptor interaction. Such agonists and antagonists are useful in the manufacture of medicaments for controlling cytokine signaling. Control of cytokine signaling is important for the treatment of a range of conditions including cancer, inflammatory conditions, immunological disorders and any other conditions involving aberrations of signal transduction.
摘要翻译：本发明一般涉及用于调节细胞因子信号传导的方法和可用于其的试剂。本发明的方法部分地基于在控制细胞因子信号传导中识别细胞因子信号传导抑制剂（SOCS）相互作用的分子靶标。分子靶标的鉴定允许开发测定以筛选可用于调节细胞因子功能的一系列激动剂和拮抗剂。因此，本发明进一步提供用于SOCS-受体相互作用的激动剂和拮抗剂的筛选测定和更特别的高通量筛选测定。这样的激动剂和拮抗剂可用于制备用于控制细胞因子信号传导的药物。细胞因子信号传导的控制对于治疗一系列病症（包括癌症，炎性病症，免疫学障碍和涉及信号转导异常的任何其他病症）是重要的。

7. 发明申请

US20130084282A1 COMPOSITIONS AND METHODS FOR TARGETING TYPE 1 INTERFERON PRODUCING CELLS 有权
公开(公告)号：US20130084282A1
公开(公告)日：2013-04-04
申请号：US13579886
申请日：2011-02-17
申请人： Gino Luigi Vairo , Andrew Nash , Eugene Maraskovsky , Nick Wilson , Samantha Busfield
发明人： Gino Luigi Vairo , Andrew Nash , Eugene Maraskovsky , Nick Wilson , Samantha Busfield
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , A61K38/1793 , A61K38/202 , A61K39/3955 , A61K51/1021 , A61K51/1033 , A61K2039/505 , C07K16/244 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76
摘要： The present disclosure provides a method for treating lupus, Sjörgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor α (IL-3Rα) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.

8. 发明申请

US20060294608A1 Novel haemopoietin receptor and genetic sequences encoding same 审中-公开
标题翻译：新型造血素受体和编码相同的遗传序列
公开(公告)号：US20060294608A1
公开(公告)日：2006-12-28
申请号：US11509410
申请日：2006-08-24
申请人： Douglas Hilton , Nicos Nicola , Alison Farley , Tracy Willson , Jian-Guo Zhang , Warren Alexander , Steven Rakar , Louis Fabri , Tetsuo Kojima , Masatsugu Maeda , Yasufumi Kikuchi , Andrew Nash
发明人： Douglas Hilton , Nicos Nicola , Alison Farley , Tracy Willson , Jian-Guo Zhang , Warren Alexander , Steven Rakar , Louis Fabri , Tetsuo Kojima , Masatsugu Maeda , Yasufumi Kikuchi , Andrew Nash
IPC分类号： A01K67/027 , C07H21/04 , C12P21/06 , C07K14/71 , C07K16/28
CPC分类号： C07K14/715 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/0381 , C07K16/2866 , C12N15/8509
摘要： The present invention relates generally to a novel haemopoietin receptor or derivatives thereof and to genetic sequences encoding same. Interaction between the novel receptor of the present invention and a cytokine ligand facilitates proliferation, differentiation and survival of a wide variety of cells. The novel receptor and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.
摘要翻译：本发明一般涉及一种新型促血细胞生成素受体或其衍生物和编码该基因的遗传序列。本发明的新型受体与细胞因子配体之间的相互作用促进多种细胞的增殖，分化和存活。本发明的新受体及其衍生物和编码本发明的遗传序列可用于开发基于配体与其受体相互作用的广泛范围的激动剂，拮抗剂，治疗剂和诊断试剂。

9. 发明申请

US20060057665A1 Galectin-14 therapeutic molecule and uses thereof 审中-公开
标题翻译： Galectin-14治疗分子及其用途
公开(公告)号：US20060057665A1
公开(公告)日：2006-03-16
申请号：US10484516
申请日：2002-07-19
申请人： Andrew Nash , Jillian Lee Dunnphy , Garry Barcham , Anna Young , Elza Nicole Meeusen
发明人： Andrew Nash , Jillian Lee Dunnphy , Garry Barcham , Anna Young , Elza Nicole Meeusen
IPC分类号： C12P21/06 , C07H21/02 , C07K14/72
CPC分类号： C07K14/4726 , A61K38/00 , C07K14/4747
摘要： The present invention relates generally to a novel galectin and to derivatives, homologues, analogues, chemical equivalents and mimetics thereof capable of modulating an immune response and, in particularly, an inflammatory response. More particularly, the present invention relates to ecalectin-like galectin (herein referred to as “galectin-14”) and to derivatives, homologues, analogues, chemical equivalents and mimetics of said protein sequence. The present invention also contemplates genetic sequences encoding said galectin and derivatives, homologues, analogues, chemical equivalents and mimetics thereof. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic applications.
摘要翻译：本发明一般涉及新型半乳凝素及其能够调节免疫应答，特别是炎症反应的衍生物，同系物，类似物，化学等同物和模拟物。更具体地，本发明涉及ecalectin样半乳凝素（本文中称为“半乳凝素-14”）以及所述蛋白质序列的衍生物，同系物，类似物，化学等价物和模拟物。本发明还考虑了编码所述半乳凝素及其衍生物，同系物，类似物，化学等价物和其模拟物的遗传序列。本发明的分子可用于一系列治疗，预防和诊断应用。

10. 发明授权

US06634692B1 Arrangement of equipment for a motor vehicle and dashboard comprising said arrangement 失效
标题翻译：包括所述装置的用于机动车辆和仪表板的设备的布置
公开(公告)号：US06634692B1
公开(公告)日：2003-10-21
申请号：US09959497
申请日：2002-04-02
申请人： Didier Barat , Andrew Nash
发明人： Didier Barat , Andrew Nash
IPC分类号： B60R706
CPC分类号： B60K37/02 , B60K2350/925 , B60K2350/945
摘要： An arrangement of equipment for a motor vehicle provided with at least one reserved space consisting of one or several side walls which are located between an opposing bottom and an opening. The reserved space in the arrangement accommodates a plurality of equipment elements respectively including at least one frame. The elements have dimensions that are equal to or multiples of a base and which fit into each other and/or do so against the side walls of the reserved space as a result of cooperation which occurs between first and second fastening devices which are provided on the frame of the elements and on the walls of the reserved space. The fixing devices are distributed in a regular manner according to the dimensions of the base.
摘要翻译：一种用于机动车辆的设备的布置，其具有由位于相对的底部和开口之间的一个或多个侧壁组成的至少一个预留空间。该布置中的保留空间容纳多个设备元件，分别包括至少一个框架。这些元件具有等于或倍数的基座并且彼此配合的尺寸和/或由于在第一和第二紧固装置之间发生的配合而在保留空间的侧壁上这样做的尺寸元素的框架和预留空间的墙壁上。固定装置根据基座的尺寸以规则的方式分布。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式